- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05873634
HeartShare: combinazione di omics, fenotipizzazione profonda e cartelle cliniche elettroniche per sottotipi di insufficienza cardiaca e obiettivi terapeutici
Studio di fenotipizzazione profonda HeartShare
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.
Panoramica dello studio
Stato
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Laura Alagna
- Numero di telefono: 312-695-6765
- Email: heartsharestudy@northwestern.edui
Luoghi di studio
-
-
California
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- University of California Davis
-
Contatto:
- Maiya Her
- Numero di telefono: 916-734-0230
-
Investigatore principale:
- Nipavan Chiamvimonvat, MD
-
Sub-investigatore:
- Javier Lopez, MD
-
Sub-investigatore:
- Martin Cadeiras, MD
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Reclutamento
- Northwestern University
-
Contatto:
- Laura Alagna
- Numero di telefono: 312-695-6765
- Email: laura.alagna@northwesterne.du
-
Investigatore principale:
- Sadiya Khan, MD
-
Investigatore principale:
- Laura Rasmussen-Torvik, PhD, MPH
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Non ancora reclutamento
- Mass General Brigham
-
Investigatore principale:
- Greg Lewis, MD
-
Contatto:
- Diane Cocca-Spofford
- Numero di telefono: 617-726-8228
- Email: dcoccaspofford@mgh.harvard.edu
-
Sub-investigatore:
- Akshay Desai, MD, MPH
-
Sub-investigatore:
- Michael Givertz, MD
-
Sub-investigatore:
- Scott Solomon, MD
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905
- Reclutamento
- Mayo Clinic
-
Investigatore principale:
- Barry Borlaug, MD
-
Sub-investigatore:
- Margaret Redfield, MD
-
Contatto:
- Matthew Adolphsen
- Numero di telefono: 507-422-5919
- Email: Adolphsen.Matthew@mayo.edu
-
-
North Carolina
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Non ancora reclutamento
- Wake Forest University
-
Contatto:
- Ben Nelson
- Numero di telefono: 336-716-6789
-
Investigatore principale:
- Dalane Kitzman, MD
-
Sub-investigatore:
- Alain Bertoni, MD, MPH
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- University of Pennsylvania
-
Contatto:
- Tiffany Sharkoski
- Numero di telefono: 215-615-2354
-
Investigatore principale:
- Julio Chirinos, MD, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adults over 30 years of age.
Descrizione
Inclusion Criteria:
HF Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).
Non-HF Group Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- No known prior diagnosis of HF or use of loop diuretics.
- No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR.
HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
-
Age ≥30 years.
-
Left ventricular ejection fraction ≥50% measured by echocardiography.
-
Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:
- Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
- Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
- Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
- Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5).
Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
- Age ≥30 years.
- Left ventricular ejection fraction ≥50% measured by echocardiography.
- No known prior diagnosis of HF or use of diuretics for fluid management.
- No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR.
- BNP <75 pg/ml or NTproBNP <225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.
Exclusion Criteria:
Exclusion Criteria (HeartShare Registry) The following exclusion criteria apply to both HF and non-HF group participants, unless otherwise indicated.
- For non-HF group: any prior known left ventricular ejection fraction <50%.
- Prior history of solid organ transplantation.
- Prior history of mechanical circulatory support.
- Prior history of non-cardiac cirrhosis.
- Inability to provide written consent to the study.
Exclusion Criteria (HeartShare Deep Phenotyping Cohort) The following exclusion criteria apply to both HFpEF and non-HFpEF group participants, unless otherwise indicated.
-
Life expectancy estimated to be < 1 year.
-
Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).
-
Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).
-
Clinically significant valvular heart disease defined as:
- Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis.
- Any mitral stenosis.
- Moderate or greater aortic regurgitation.
- Greater than moderate mitral regurgitation.
-
Any planned cardiac surgery or cardiac intervention in the next 3 months.
-
Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.
-
Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.
-
Known symptomatic epicardial coronary artery disease that is not revascularized.
-
Any non-elective hospitalization in the preceding 2 weeks.
-
Prior history of solid organ transplantation.
-
Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.
-
Prior history of mechanical circulatory support.
-
Prior history of non-cardiac cirrhosis.
-
Estimated GFR <20 ml/min/1.73m2 or currently on dialysis.
-
Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.
-
Inability to provide written consent to the study.
-
Current acute decompensated heart failure.
-
Currently pregnant.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
HFpEF
Participants with HFpEF |
|
Non-HFpEF
Participants without HFpEF |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Numero di partecipanti con insufficienza cardiaca con frazione di eiezione preservata (HFpEF)
Lasso di tempo: Fino a 5 anni
|
Fino a 5 anni
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Sanjiv Shah, MD, Northwestern University
- Cattedra di studio: Svati Shah, MD, MHS, Duke University
- Cattedra di studio: Javed Butler, MPH, MBA, Baylor Scott and White Health
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- STU00217900
- U54HL160273 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .